CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
Simon J. Harrison, Cyrille Touzeau, Nicolas Kint, Katherine Li, Tamia Nguyen, Caroline Mayeur‐Rousse, Marzia Rahman, Yannick Le Bris, Jeremy Er, Juliette Eugene-Lamer, Nicole M. Haynes, Jessica Li, Rebecca C Abbott, Caroline Bodet‐Milin, Anne Moreau, Éric Letouzé, Nikoletta Lendvai, Jordan M. Schecter, William Deraedt, Arnob Banerjee, Tamar Lengil, Martin Vogel, Brad Foulk, Hao Zhao, Denis A. Smirnov, Ana Slaughter, Carolina Lonardi, Erin Lee, Loreta Marquez, Ayah Sankari, Vicki Plaks, José Varela Donato Filho, Nitin Patel, Dong Geng, Thomas Gastinne, Hannah G. Kelly, Ing Soo Tiong, Marion Eveillard, Patrice Chevallier, Stephen Lade, Philippe Moreau, Sean M. Grimmond, Jane Oliaro, Benoît Tessoulin, Piers Blombery
Abstract
-mutated T cells, followed by acquisition of further oncogenic genomic variants. Other potential contributors include germline genomic variation, viral infections, and previous treatment for myeloma. In the absence of direct evidence, the contribution of insertional mutagenesis to the development of T-cell lymphoma is currently unclear. (Funded by Johnson & Johnson and Legend Biotech USA; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).